1.3 C
New York
Tuesday, January 31, 2023

This Is Too Hot For MannKind Corporation (NASDAQ: MNKD), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for MannKind Corporation (MNKD) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 0.66%, to $4.60. The MannKind Corporation has recorded 38,935 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

As a NASDAQ listed company, MNKD falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $4.57 and fluctuated between $4.8350 as its day high and $4.5550 as its day low. The current market capitalization of MannKind Corporation is $1.24B. A total of 2.93 million shares were traded on the day, compared to an average of 4.52M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, MNKD has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 218,500 and the disposition of 0 shares. Over the last 12 months, there were 39 BUYs and 14 SELLs from insiders. Insiders purchased 2,154,449 shares during that period but sold 147,434.

In the most recent transaction, Thomson David sold 7,000 shares of MNKD for 3.67 per share on Aug 29. After the transaction, the EVP Genl Counsel & Secretary now owns 726,035 company shares. In a previous transaction on Aug 22, Galindo Alejandro sold 4,615 shares at 3.85 per share. MNKD shares that EVP Endocrine Business Unit owns now total 777,075.

Among the insiders who bought shares, Galindo Alejandro acquired of 5,000 shares on Jul 31 at a per-share price of $2.93. This resulted in the EVP Endocrine Business Unit holding 781,690 shares of MNKD after the transaction. In another insider transaction, Tross Stuart A bought 4,581 shares at $2.93 per share on Jul 31. Company shares held by the Chief People & Workpl Officer now total 830,650.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for MNKD in the last 3 months, the mean price target is $6.17 with high estimates of $8.00 and low estimates of $5.00. In terms of 52-week highs and lows, MNKD has a high of $5.47 and a low of $2.49.

As of this writing, MNKD has an earnings estimate of -$0.09 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.13.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MNKD is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles